title: Circadian variation of total ischaemic burden and its alteration with anti-anginal agents.
abstract: 6264 hours of ambulatory ST segment monitoring of 150 unselected patients with proven coronary artery disease, who were off all routine anti-anginal treatments, showed 598 ischaemic episodes, of which 446 (75%) were silent (symptom-free). Most (68%) ischaemic episodes occurred between 0730 and 1930, with a peak in the morning and a lesser peak in the evening. Two subgroups were studied further in double-blind controlled trials: 33 patients had a total of 1313 hours of ST segment monitoring while treated with nifedipine; and 41 patients a total of 1581 hours while treated with atenolol. Nifedipine did not alter the circadian pattern of ischaemic episodes; atenolol abolished the morning peak, and the peak incidence of ischaemia then occurred in the evening. Circadian patterns for total duration of ischaemic episodes corresponded closely to those of episodes of ischaemia, and were similarly altered by treatment. The circadian pattern of silent ischaemic episodes and their total duration were very similar to those of total ischaemia for the group as a whole and the different subgroups. This circadian distribution of ischaemic episodes and the observed changes with treatment resemble the reported circadian variation of acute myocardial infarction and sudden death.
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use*; D002940:Circadian Rhythm / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology*; D003645:Death, Sudden; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D005583:Fourier Analysis; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D001262:Atenolol; D009543:Nifedipine